42 related articles for article (PubMed ID: 23121604)
1. Expression of EZH2 in renal cell carcinoma as a novel prognostic marker.
Lee HW; Choe M
Pathol Int; 2012 Nov; 62(11):735-41. PubMed ID: 23121604
[TBL] [Abstract][Full Text] [Related]
2. MTOR modulation induces selective perturbations in histone methylation which influence the anti-proliferative effects of mTOR inhibitors.
Kim H; Lebeau B; Papadopoli D; Jovanovic P; Russo M; Avizonis D; Morita M; Afzali F; Ursini-Siegel J; Postovit LM; Witcher M; Topisirovic I
iScience; 2024 Mar; 27(3):109188. PubMed ID: 38433910
[TBL] [Abstract][Full Text] [Related]
3. The clinicopathological and prognostic significances of EZH2 expression in urological cancers: A meta‑analysis and bioinformatics analysis.
Bai YK; Sun J; Wang YS; Zheng N; Xu QL; Wang Y
Oncol Lett; 2023 Jul; 26(1):315. PubMed ID: 37346412
[TBL] [Abstract][Full Text] [Related]
4. EZH2-regulated immune risk score prognostic model predicts outcome of clear cell renal cell carcinoma.
Xu S; Ma B; Feng X; Yao C; Jian Y; Chen Y; Wang X; Xie H; Li L
Transl Androl Urol; 2023 Jan; 12(1):71-82. PubMed ID: 36760869
[TBL] [Abstract][Full Text] [Related]
5. H3K27me3 in Diffuse Midline Glioma and Epithelial Ovarian Cancer: Opposing Epigenetic Changes Leading to the Same Poor Outcomes.
Day CA; Hinchcliffe EH; Robinson JP
Cells; 2022 Oct; 11(21):. PubMed ID: 36359771
[TBL] [Abstract][Full Text] [Related]
6. Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma?
Krossa I; Strub T; Aplin AE; Ballotti R; Bertolotto C
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230787
[TBL] [Abstract][Full Text] [Related]
7. An overview of the development of EED inhibitors to disable the PRC2 function.
Liu KL; Zhu K; Zhang H
RSC Med Chem; 2022 Jan; 13(1):39-53. PubMed ID: 35224495
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Regulation of EMT (Epithelial to Mesenchymal Transition) and Tumor Aggressiveness: A View on Paradoxical Roles of KDM6B and EZH2.
Lachat C; Boyer-Guittaut M; Peixoto P; Hervouet E
Epigenomes; 2018 Dec; 3(1):. PubMed ID: 34991274
[TBL] [Abstract][Full Text] [Related]
9. Regulating Methylation at H3K27: A Trick or Treat for Cancer Cell Plasticity.
Das P; Taube JH
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33003334
[TBL] [Abstract][Full Text] [Related]
10. Genomic profiling in renal cell carcinoma.
Dizman N; Philip EJ; Pal SK
Nat Rev Nephrol; 2020 Aug; 16(8):435-451. PubMed ID: 32561872
[TBL] [Abstract][Full Text] [Related]
11. High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma.
Eichenauer T; Simmendinger L; Fraune C; Mandelkow T; Blessin NC; Kluth M; Hube-Magg C; Möller K; Clauditz T; Weidemann S; Dahlem R; Fisch M; Riechardt S; Simon R; Sauter G; Büscheck F; Rink M
World J Urol; 2021 Feb; 39(2):481-490. PubMed ID: 32303902
[TBL] [Abstract][Full Text] [Related]
12. A novel EZH2 inhibitor induces synthetic lethality and apoptosis in PBRM1-deficient cancer cells.
Huang K; Sun R; Chen J; Yang Q; Wang Y; Zhang Y; Xie K; Zhang T; Li R; Zhao Q; Zou L; Li J
Cell Cycle; 2020 Apr; 19(7):758-771. PubMed ID: 32093567
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Krill L; Deng W; Eskander R; Mutch D; Zweizig S; Hoang B; Ioffe O; Randall L; Lankes H; Miller DS; Birrer M
Gynecol Oncol; 2020 Feb; 156(2):423-429. PubMed ID: 31843273
[TBL] [Abstract][Full Text] [Related]
14. G Protein γ subunit 7 loss contributes to progression of clear cell renal cell carcinoma.
Xu S; Zhang H; Liu T; Chen Y; He D; Li L
J Cell Physiol; 2019 Nov; 234(11):20002-20012. PubMed ID: 30945310
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor β promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network.
Ding J; Yeh CR; Sun Y; Lin C; Chou J; Ou Z; Chang C; Qi J; Yeh S
Oncogene; 2018 Sep; 37(37):5037-5053. PubMed ID: 29789714
[TBL] [Abstract][Full Text] [Related]
16. EZH2 enhances the invasive capability of renal cell carcinoma cells via activation of STAT3.
Zhang D; Yang XJ; Luo QD; Fu DL; Li HL; Li HC; Zhang P; Chong T
Mol Med Rep; 2018 Mar; 17(3):3621-3626. PubMed ID: 29286132
[TBL] [Abstract][Full Text] [Related]
17. Functional and therapeutic significance of EZH2 in urological cancers.
Liu X; Wu Q; Li L
Oncotarget; 2017 Jun; 8(23):38044-38055. PubMed ID: 28410242
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
Christofides A; Karantanos T; Bardhan K; Boussiotis VA
Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
[TBL] [Abstract][Full Text] [Related]
19. Decreased expression of long non-coding RNA NBAT-1 is associated with poor prognosis in patients with clear cell renal cell carcinoma.
Xue S; Li QW; Che JP; Guo Y; Yang FQ; Zheng JH
Int J Clin Exp Pathol; 2015; 8(4):3765-74. PubMed ID: 26097558
[TBL] [Abstract][Full Text] [Related]
20. Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysis.
Chen S; Huang L; Sun K; Wu D; Li M; Li M; Zhong B; Chen M; Zhang S
PLoS One; 2015; 10(5):e0125480. PubMed ID: 25974088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
